BIOGNOSYS
21.10.2021 16:02:05 CEST | Business Wire | Press release
Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, today announced they will be presenting major scientific and technological advances on their proprietary proteomics research services, software, and kits at the American Society for Mass Spectrometry (ASMS) Annual Conference from October 31st to November 4th in Philadelphia (USA).
Biognosys will present a record number of 3 oral presentations, 10 scientific posters, 2 poster collaborations, 1 workshop panel, and 2 Spectronaut™ breakfast seminars . In addition, their team of scientific experts will be present at booth #224 to answer questions and demo software. Further demo sessions will be offered at the Bruker Daltonics booth #719.
Collectively, this presence demonstrates Biognosys’ significant contributions to transforming life science and clinical research with next-generation proteomics, particularly in the areas of plasma proteomics, immunopeptidomics, and proteomics data analysis.
Lukas Reiter, PhD, Chief Technology Officer of Biognosys:
“Our major contribution to the ASMS scientific program is a testimony of Biognosys’ relentless commitment to innovation in mass spectrometry-based proteomics and progress in life science and clinical research.”
Discovering biomarkers in cancer with next-generation plasma proteomics
The plasma proteome is an underexplored source of insights on the health state of an individual. Biognosys will present results from a deep human plasma profiling study on a cohort of 180 lung, breast, colorectal, pancreatic, and prostate cancer patients, using an early version of their next-generation Plasma Biomarker Discovery workflow, launching in November. The workflow is optimized for use on Thermo Fisher Scientific Exploris 480 and FAIMS Pro instruments. Out of the entire plasma proteome, they quantified over 2,700 proteins and identified a protein panel with a significant positive predictive value for individual cancer stages.
Andreas Huhmer, Senior Director Life Sciences Research OMICS Marketing
at Thermo Fisher Scientific:
“Biognosys has a proven track record for maximizing all innovative features of the Thermo Scientific™ Orbitrap™ mass spectrometers in state-of-the-art proteome analysis. Their new Plasma Biomarker Discovery workflow is a good example of this. The unprecedented depth and quantitative precision they can achieve, coupled with the inherently unbiased nature of mass spectrometry-based analysis, has the potential to take plasma biomarker discovery to the next level.”
Gaining insights on the immune system to support personalized drug development
Immunopeptides play an essential role in the immune system and can be analyzed to support the development of personalized treatments. Mass spectrometry is currently the only technology that can reliably measure and identify immunopeptide profiles of biological samples on a large scale. Biognosys will present their immunopeptidomics workflow, optimized to provide deep and comprehensive biological insights on the immune system in large-scale clinical studies.
Turning data to insights with Spectronaut™, SpectroMine™, and SpectroDive™
Biognosys provides leading software products for proteomics data analysis. In a series of talks, their team will detail how they leverage the latest developments in Machine Learning and Deep Learning to allow deeper insights into the proteome. Biognosys is also excited to host two breakfast seminars with three guest speakers sharing their latest results from using Spectronaut in their research projects. In addition, a sneak-peak into the next planned release will be disclosed.
Gary Kruppa, Vice President, Proteomics at Bruker Daltonics:
“Biognosys’ software tools are among the top solutions for the analysis of proteomics data generated with Bruker instruments. Particularly the latest Spectronaut version yields spectacular performance improvements for dia-PASEF data. We invite all Bruker users to experience Spectronaut’s capabilities and enjoy the exceptional support Biognosys provides.”
Visit biognosys.com/asms2021 for a complete overview of Biognosys’ presence at ASMS.
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005530/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Charted Launches ERP-Native E-invoicing Across EMEA1.9.2026 14:30:00 CEST | Press release
Expansion will bring Charted E-invoicing across Europe, supporting accounts payable operations with a fully compliant invoicing process that remains embedded inside their ERP Charted, a leading accounts payable automation software and ERP services provider, today announced the expansion of Charted E-invoicing to support multiple countries spanning Europe, including Germany, France, Norway, Sweden, the Netherlands, Denmark and Finland. Further expansion to Italy, Romania, and Poland, will take place by the end of the quarter. These countries follow the official launch of Charted E-invoicing in Belgium, in May 2026. This expansion is designed to cement Charted support for users across EMEA, ensuring companies based in the region transacting on the PEPPOL network can remain compliant while keeping their accounts payable processes embedded inside their ERP. Charted E-invoicing works as a capability within Charted Invoice AI, to receive electronic invoices directly into the AP inbox, keepin
Riskified Expands its Risk Intelligence Platform with ARIA1.9.2026 14:00:00 CEST | Press release
AI Risk Intelligence Analyst (ARIA) gives fraud teams instant answers from their order data, helping them investigate patterns, drill into trends, and act on insights directly within the Riskified Control Center Riskified (NYSE: RSKD), a global leader in ecommerce fraud detection and risk intelligence, today expanded its risk intelligence platform with ARIA (AI Risk Intelligence Analyst), a conversational AI capability built directly into the Riskified Control Center. Fraud teams today have access to vast amounts of data, but solving urgent business questions often still requires exporting files, building reports, or waiting for additional analysis. ARIA changes that by letting merchants ask questions in natural language and get answers in seconds, complete with charts and tables that support the analysis. With direct access to Riskified metrics and their own business-specific reporting logic, ARIA can investigate and quickly answer a wide range of questions within an existing workflow
Vasion® Unlocks Windows PCs on Snapdragon Adoption with Native, Driverless Printing1.9.2026 14:00:00 CEST | Press release
Eliminating One of the Last Barriers to Enterprise Windows Modernization Vasion is removing a critical barrier to modern Windows device adoption with native, driverless printing for PCs powered by Snapdragon® compute processors. The Vasion Spring 2026 release delivers a seamless, cloud-native print experience, eliminating the need for printer drivers, emulation, or parallel print environments. The collaboration with Qualcomm Technologies combines the PC ecosystem reach of Snapdragon with Vasion's print automation expertise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901581087/en/ Vasion fully supports Windows devices powered by Snapdragon with full Internet Printing Protocol (IPP) driverless printing support, enabling IT teams to modernize device fleets without disrupting operations or rearchitecting existing environments. Vasion fully supports Windows devices powered by Snapdragon with full Internet Printing Protocol
Perma-Pipe and Welspun Announce Memorandum of Understanding to Establish Pipe Manufacturing and Coating Facilities in Jordan1.9.2026 14:00:00 CEST | Press release
Strategic Partnership to Establish Integrated Pipe Manufacturing and Coating Capabilities to Support Water, Oil & Gas, and Infrastructure Projects in Jordan and the Levant Region. Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) (“Perma-Pipe” or the “Company”), a global leader in engineered pipe solutions specialising in anti-corrosion coatings, insulation solutions, containment systems, custom fabrication and leak detection, today announced that it has signed, together with Welspun Corp Limited (“Welspun”), a Memorandum of Understanding (“MOU”) with the developers of Jordan’s National Water Carrier Project and the Government of the Hashemite Kingdom of Jordan to advance the development of pipe manufacturing and advanced coating facilities in Jordan. The parties intend to establish a joint venture to support the development and operation of these facilities. Transaction Description Under the terms of the MOU, Perma-Pipe and Welspun have partnered to establish an integrated pipe m
Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 20261.9.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 2026 Cantor Global Healthcare Conference on September 9, 2026 and will participate in a fireside chat at 3:20pm ET and a panel entitled “PSYCH! Accessing The New Wave of Psychedelics” at 4:30pm ET. A live audio webcast of the fireside chat will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resis
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom